Recurrent glioblastoma (rGB) patients in Medicenna Therapeutics’ (TSXV:MDNA) Phase 2b clinical trial of MDNA55, a targeted immunotherapy agent, have been treated at three clinical centers in the U.S. using innovative drug delivery technology from Brainlab.
The investigators used convection-enhanced delivery (CED) to inject MDNA55, together with an imaging agent, directly into the tumor. When combined with real-time image-guided magnetic resonance imaging, CED allows delivery of MDNA55 at high concentrations into the tumour tissue while avoiding exposure to the rest of the body.
The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
Precise targeting is an integral part in the treatment of brain tumors to achieve significant coverage. "Brainlab brings advanced tools for planned and controlled delivery to this trial,” Rowena Thomson, drug delivery manager at Brainlab, said in a statement.
"With Medicenna, we have found one of the most experienced teams for targeted drug delivery as a key partner in the development of therapies for brain tumors,” she added. “Using iPlan Flow and VarioGuide, neurosurgeons will be able to plan treatments and catheter placement for delivery and distribution of MDNA55."
Designed specifically for planning drug delivery procedures, iPlan Flow software determines trajectories and infusion parameters based on patient-specific image data. The combination of this technology with clinical trial support services allows Brainlab to offer a comprehensive drug delivery solution to pharmaceutical companies.